---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021115"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:07:43.777093+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q1 2024 revenue $10.0M, net loss $40.6M; pipeline metrics grow

## Summary
- Revenue of $10.0M ($9.8M research fees, $0.2M licensing) down 18% from $12.2M in Q1 2023.
- Net loss of $40.6M ($0.14 per share) compared to net loss of $40.1M in Q1 2023.
- R&D expenses fell to $39.3M from $52.6M; cash & securities $725.3M plus $240M non-dilutive funding.
- Cumulative partner-initiated program starts 90 (up 20% YoY) and molecules in clinic 13 (up 44% YoY).
- Announced collaborations with Biogen for neurological antibodies and with Viking/ArrowMark to launch biotechs.

## SEC filing metadata
- accession: 0001628280-24-021115
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/0001628280-24-021115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/abcl-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021115
- JSON: https://secwatch.observer/filing/0001628280-24-021115.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021115.txt

## Key facts
- Earnings Releases
  AbCellera Biologics Inc. reported quarter ended March 31, 2024 results: revenue $10.0 million, net income Net loss of $40.6 million, EPS $(0.14) per share.
  - Period: quarter ended March 31, 2024
  - Revenue: $10.0 million
  - Net income: Net loss of $40.6 million
  - EPS: $(0.14) per share
  - Result: reported results
  source text: ● Revenue – Total revenue was $10.0 million, compared to $12.2 million in Q1 2023. Partnerships generated research fees of $9.8 million, compared to $10.6 million in Q1 2023. Licensing revenue was $0.2 million. ● Research & Development (R&D) Expenses – R&D expenses were $39.3 million, compared to $52.6 million in Q1 2023, reflecting underlying continued growth in program execution, platform development, and investments in internal programs, partially offset by the non-recurrence of specific one-time investments in co-development and internal programs. ● Sales & Marketing (S&M) Expenses – S&M expenses were $3.4 million, compared to $3.8 million in Q1 2023. ● General & Administrative (G&A) Expenses – G&A expenses were $17.4 million, compared to $15.1 million in Q1 2023. ● Net Loss – Net loss of $40.6 million, or $(0.14) per share on a basic and diluted basis, compared to net loss of $40.1 million, or $(0.14) per share on a basic and diluted basis in Q1 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/0001628280-24-021115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.